Brain Cancer Trial, Recruiting NCT06211257 Sponsor: Centre Oscar Lambret Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT06211257
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with sarcoma (a type of cancer) affecting soft tissues or internal organs
  • People whose cancer cannot be removed by surgery and has either spread to other parts of the body or has grown significantly in a local area
  • People for whom a doctor has recommended treatment with one of the following medicines as a single drug: pazopanib, trabectedine, eribulin, ifosfamide, or dacarbazine
  • People who are covered by French social security
  • People who have read, understood, and signed a consent form agreeing to take part

Who may not be able to join:

  • People who have already taken part in the ePPS trial for a previous cancer treatment
  • People who have significant difficulty reading or understanding French
  • People who have difficulty accessing or using a computer
  • People who are pregnant or currently breastfeeding
  • People who are under legal guardianship or whose freedom is restricted by law
  • People for whom regular medical follow-up would not be possible due to geographical, social, or psychological reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Diane PANNIER, MD, Centre Oscar Lambret

Phone: 03.20.29.59.59

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Oscar Lambret
Registry
ClinicalTrials.gov
Start date
29 May 2024
Est. completion
1 July 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Severe toxicity in the first 3 months of treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov